Gilead Sciences vs Regeneron Pharmaceuticals
Gilead Sciences reported revenue of $29.4 billion in fiscal 2025, 2.1 times Regeneron Pharmaceuticals' $14.3 billion in fiscal 2025. Gilead Sciences' revenue grew 2.4% in its latest year, and Regeneron Pharmaceuticals' grew 1.0%. Gilead Sciences had an operating margin of 34.0%, against 24.9% at Regeneron Pharmaceuticals. Free cash flow was $9.5 billion at Gilead Sciences and $4.1 billion at Regeneron Pharmaceuticals.
Side by side
| Gilead Sciences | Regeneron Pharmaceuticals | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $29.4B | $14.3B |
| Revenue growth | 2.4% | 1.0% |
| Revenue growth a year, last 5 years | 3.6% | 11.0% |
| Gross margin | 78.8% | — |
| Operating margin | 34.0% | 24.9% |
| Net margin | 28.9% | 31.4% |
| Free cash flow | $9.5B | $4.1B |
| Free cash flow margin | 32.1% | 28.4% |
| Return on capital | 22.9% | 12.7% |
| Net debt to EBITDA | 1.4x | −1.4x |
| Dividends and buybacks | $5.9B | $3.8B |
| Change in diluted share count | 0.0% | −5.7% |
| Last close | $158.69 | $807.67 |
| P/E at the last close | — | 20.0× |
| Insider trades, last 12 months | sold $85.8 million | sold $16.1 million |
| Piotroski F-score | 8 of 9 | 5 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Gilead SciencesRegeneron Pharmaceuticals
Operating margin
Percent of revenue
Gilead SciencesRegeneron Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Gilead SciencesRegeneron Pharmaceuticals
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Gilead Sciences and Regeneron Pharmaceuticals pages.